Cancer medicine · 2026
SLC12A8 Drives Immune Evasion and Metastasis in Luminal B Breast Cancer by Inducing CD8+ T-Cell Exhaustion via the TLR Signaling Pathway.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Liu Zhiyong, Chen Ran
Аннотация
BACKGROUND: To investigate the role and mechanism of SLC12A8 in the progression of Luminal B breast cancer.
METHODS: Data from TCGA, GTEx, and HPA databases were used to analyze SLC12A8 expression and its prognostic value in breast cancer. qPCR was performed to validate SLC12A8 expression in various breast cancer cell lines. The correlation between SLC12A8 and immune cell infiltration was analyzed using ImmuCellAI and TIMER databases. Gene set enrichment analysis (GSEA) was employed to predict signaling pathways associated with SLC12A8. In vitro, siRNA-mediated knockdown of SLC12A8 or treatment with the TLR pathway inhibitor GIT27 was used to assess the effects on the TLR pathway, CD8+ T cell function (as indicated by PD-1, PRF1, and GZMB expression), and cancer cell invasion via Western blot, immunofluorescence, qPCR, and Transwell assays. CD8+ T cells were isolated from healthy human peripheral blood using magnetic bead separation (Miltenyi Biotec, CD8 MicroBeads) and activated with anti-CD3/CD28 beads prior to co-culture. Additional functional assays included IFN-γ/IL-2 ELISA and cytotoxicity assays.
RESULTS: SLC12A8 was significantly upregulated in breast cancer tissues and cell lines, and its high expression correlated with poor patient prognosis. Bioinformatic analysis and experimental validation confirmed that high SLC12A8 expression was strongly associated with reduced infiltration and functional inhibition of CD8+ T cells in the tumor microenvironment, particularly in Luminal B breast cancer. Mechanistically, SLC12A8 activated the TLR signaling pathway (upregulating TLR2, MyD88, IRAK1, TAK1 in CD8+ T cells), leading to increased PD-1 expression on CD8+ T cells, resulting in their functional exhaustion and enhanced invasive ability of Luminal B breast cancer cells. Knockdown of SLC12A8 or TLR pathway inhibition reversed these effects. Overexpression of SLC12A8 in normal breast epithelial cells recapitulated the exhausted T-cell phenotype, and TLR2 agonist treatment mimicked SLC12A8 effects.
CONCLUSION: SLC12A8 promotes immune evasion and metastasis in Luminal B breast cancer by inducing CD8+ T-cell exhaustion via activation of the TLR signaling pathway, suggesting its potential as a prognostic biomarker and therapeutic target.
METHODS: Data from TCGA, GTEx, and HPA databases were used to analyze SLC12A8 expression and its prognostic value in breast cancer. qPCR was performed to validate SLC12A8 expression in various breast cancer cell lines. The correlation between SLC12A8 and immune cell infiltration was analyzed using ImmuCellAI and TIMER databases. Gene set enrichment analysis (GSEA) was employed to predict signaling pathways associated with SLC12A8. In vitro, siRNA-mediated knockdown of SLC12A8 or treatment with the TLR pathway inhibitor GIT27 was used to assess the effects on the TLR pathway, CD8+ T cell function (as indicated by PD-1, PRF1, and GZMB expression), and cancer cell invasion via Western blot, immunofluorescence, qPCR, and Transwell assays. CD8+ T cells were isolated from healthy human peripheral blood using magnetic bead separation (Miltenyi Biotec, CD8 MicroBeads) and activated with anti-CD3/CD28 beads prior to co-culture. Additional functional assays included IFN-γ/IL-2 ELISA and cytotoxicity assays.
RESULTS: SLC12A8 was significantly upregulated in breast cancer tissues and cell lines, and its high expression correlated with poor patient prognosis. Bioinformatic analysis and experimental validation confirmed that high SLC12A8 expression was strongly associated with reduced infiltration and functional inhibition of CD8+ T cells in the tumor microenvironment, particularly in Luminal B breast cancer. Mechanistically, SLC12A8 activated the TLR signaling pathway (upregulating TLR2, MyD88, IRAK1, TAK1 in CD8+ T cells), leading to increased PD-1 expression on CD8+ T cells, resulting in their functional exhaustion and enhanced invasive ability of Luminal B breast cancer cells. Knockdown of SLC12A8 or TLR pathway inhibition reversed these effects. Overexpression of SLC12A8 in normal breast epithelial cells recapitulated the exhausted T-cell phenotype, and TLR2 agonist treatment mimicked SLC12A8 effects.
CONCLUSION: SLC12A8 promotes immune evasion and metastasis in Luminal B breast cancer by inducing CD8+ T-cell exhaustion via activation of the TLR signaling pathway, suggesting its potential as a prognostic biomarker and therapeutic target.